Resistance is futile: Targeting the inhibitory Fcg gamma RIIB (CD32B) to maximize immunotherapy

Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory Fc gamma RIIB. We recently developed mAbs to block Fc gamma RIIB and provided in vivo proof-of-concept for their ability to overcome Fc gamma RIIB-mediated resistance.